A Caltech Library Service

Targeted Gene Therapy with Engineered Systemic AAVs for the Central and Peripheral Nervous Systems Prevents Motor Coordination Phenotypes in a Mouse Model of Friedreich’s Ataxia

Hori, Acacia and Grebin, Anastasiya and Robinson, J. Elliott and Chen, Xinhong and Flytzanis, Nick and Goeden, Nick and Chan, Ken and Deverman, Ben and Gradinaru, Viviana (2021) Targeted Gene Therapy with Engineered Systemic AAVs for the Central and Peripheral Nervous Systems Prevents Motor Coordination Phenotypes in a Mouse Model of Friedreich’s Ataxia. Molecular Therapy, 29 (4, S1). p. 125. ISSN 1525-0016.

[img] PDF - Published Version
See Usage Policy.


Use this Persistent URL to link to this item:


Friedreich’s Ataxia (FA) is a genetic disease characterized by progressive ataxia and cardiomyopathy. In FA, insufficient expression of frataxin (FXN) increases cell susceptibility to damage from oxidative stress. Neuronal degeneration in the deep cerebellar nuclei and dorsal root ganglia (DRGs) cause loss of motor coordination, while cardiomyopathy in FA contributes to early death. Systemically delivered AAVs can non-invasively target genetic cargo to diverse sites throughout the body, with some serotypes able to reach the CNS. However, at high doses, these vectors can cause severe toxicity, emphasizing the need for targeted, efficient gene delivery vectors. In this study, we used engineered AAVs to target FXN to cell types of pathophysiologic relevance to FA, while de-targeting the liver and cell types typically spared in human disease. A DNA plasmid containing FXN and its putative gene regulatory elements and control constructs were packaged into AAV.CAP-B10[1] and AAV-PHP.PNS2, two next generation systemic AAVs that have demonstrated transduction biases toward CNS and PNS respectively. A cocktail of both capsids packaging either the FXN or control cargo were delivered intravenously to a pilot cohort of young adult FA model mice (inducible shRNA-based FXN knockdown mice (FXNiKD)[2], n=7 per group) 12 weeks prior to doxycycline-induction of the disease phenotype. Motor, sensory and cardiac function was assessed using the beam traversal test, gait analysis, weightlifting and electrocardiography before quantitative tissue analysis was performed to assess FXN levels and pathologic hallmarks. Exogenous FXN expression mimicked the endogenous patterns of non-diseased mice in the CNS and DRGs, with reduced liver expression. Importantly, prophylactic AAV-FXN expression prevented induction of motor and coordination deficits as measured by foot slips and time to traverse the narrowing beam, compared to controls, with performance resembling wildtype littermates. We are investigating whether it is also possible to reverse existing motor deficits and pathology in mice using targeted AAV-FXN intervention after induction of the disease phenotype. These findings demonstrate the utility of engineered AAVs for pre-clinical research to test precision gene therapies in neurodegenerative disease models.

Item Type:Article
Related URLs:
URLURL TypeDescription
Hori, Acacia0000-0001-5868-348X
Robinson, J. Elliott0000-0001-9417-3938
Chen, Xinhong0000-0003-0408-0813
Flytzanis, Nick0000-0002-7921-9392
Chan, Ken0000-0002-8853-5186
Deverman, Ben0000-0002-6223-9303
Gradinaru, Viviana0000-0001-5868-348X
Additional Information:© 2021 American Society of Gene & Cell Therapy. Available online 27 April 2021.
Issue or Number:4, S1
Record Number:CaltechAUTHORS:20210528-082042148
Persistent URL:
Official Citation:ASGCT Annual Meeting Abstracts, Molecular Therapy, Volume 29, Issue 4, Supplement 1, 2021, Pages 1-427, ISSN 1525-0016, (
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:109292
Deposited By: Tony Diaz
Deposited On:28 May 2021 15:30
Last Modified:28 May 2021 15:30

Repository Staff Only: item control page